T1	p 51 69	premature monkey :
T2	p 196 276	premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD )
T3	i 81 106	antenatal dexamethasone .
T4	i 137 171	antenatal glucocorticoid treatment
T5	i 222 234	nemestrina )
T6	i 286 330	dams received dexamethasone ( 2 mg/dose ) 72
T7	i 354 363	abdominal
T8	i 438 446	saline .
T9	i 458 484	dexamethasone-treated dams
T10	i 1512 1525	dexamethasone
T11	i 1623 1646	Antenatal dexamethasone
T12	o 503 538	lower incidence and severity of HMD
T13	o 615 626	Improvement
T14	o 707 734	volume-pressure behavior of
T15	o 747 787	lungs included greater distensibility in
T16	o 805 826	dexamethasone-treated
T17	o 915 934	deflation stability
T18	o 940 1023	treatment . Accelerated production of surface active material ( SAM ) phospholipids
T19	o 1097 1120	total lung phospholipid
T20	o 1194 1228	alveolar lavage fluid phospholipid
T21	o 1301 1368	, and alveolar lavage fluid disaturated phosphatidylcholine ( DPC )
T22	o 1443 1489	Incorporation of 14C-palmitate into lung lipid
T23	o 1688 1710	incidence and severity
T24	o 1823 1862	maturation of fetal pulmonary functions
T25	o 1922 1925	SAM